Dual Therapy With Anti-CGRP Monoclonal Antibodies and Botulinum Toxin for Migraine Prevention: Is There a Rationale?

Lanfranco PellesiThien P DoHåkan AshinaAnne Luise Haulund VollesenRami Burstein

Published in: Headache (2020)

There is currently only indirect preclinical evidence to support a rationale for dual therapy with anti-calcitonin gene-related peptide monoclonal antibodies and botulinum toxin type A for chronic migraine prevention. Rigorous studies evaluating clinical efficacy, safety, and cost-effectiveness are needed.

Keyphrases

botulinum toxin
copy number
cell therapy
stem cells
gene expression
bone marrow
mesenchymal stem cells